Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of single-agent ofatumumab in relapsed or refractory mantle cell lymphoma
ISRCTN32524443Phase 2Completed
- Sponsor
- University Hospitals Plymouth
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in mantle cell lymphoma (MCL), sponsored by University Hospitals Plymouth. Primary endpoints: Complete response rate and Interim futility/continuation analysis. Started Jan 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ISRCTN32524443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN32524443.